- Home
- GILD
GILD
Gilead Sciences Inc.
as 02-21-2025 4:00pm EST
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 119.7B | IPO Year: | 1992 |
| Target Price: | $101.88 | AVG Volume (30 days): | 7.6M |
| Analyst Decision: | Buy | Number of Analysts: | 27 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 0.38 | EPS Growth: | -91.56 |
| 52 Week Low/High: | $62.07 - $111.03 | Next Earning Date: | 02-11-2025 |
| Revenue: | $28,754,000,000 | Revenue Growth: | 6.04% |
| Revenue Growth (this year): | 0.82% | Revenue Growth (next year): | 3.21% |
Stock Insider Trading Activity of Gilead Sciences Inc. (GILD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | GILD | 10% Owner | Feb 18 '25 | Buy | $11.00 | 1,363,636 | $14,999,996.00 | 31,424,760 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Feb 18 '25 | Sell | $104.09 | 2,500 | $260,225.00 | 169,061 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Feb 12 '25 | Sell | $102.22 | 137,676 | $14,073,240.72 | 169,061 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Jan 31 '25 | Sell | $97.22 | 142,180 | $13,822,739.60 | 169,061 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Jan 15 '25 | Sell | $91.35 | 2,500 | $228,375.00 | 169,061 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Dec 16 '24 | Sell | $91.96 | 8,500 | $781,660.00 | 169,061 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Nov 29 '24 | Sell | $92.76 | 248,645 | $23,065,270.54 | 169,061 | |
| Parsey Merdad | GILD | Chief Medical Officer | Nov 27 '24 | Sell | $91.88 | 164,211 | $15,094,013.40 | 99,599 | |
| Bluestone Jeffrey | GILD | Director | Nov 26 '24 | Sell | $91.39 | 6,788 | $620,356.00 | 8,920 |
Latest Gilead Sciences Inc. News
GILD Breaking Stock News: Dive into GILD Ticker-Specific Updates for Smart Investing
Simply Wall St.
18 hours ago
Some Investors May Be Willing To Look Past Gilead Sciences' (NASDAQ:GILD) Soft Earnings
Quartz
a day ago
Gilead's new HIV med, a bird flu shot for chickens, and Hims does blood tests: Pharma news roundup
MT Newswires
a day ago
Gilead Sciences Gets Conditional Marketing Authorization for Liver Disease Treatment in European Economic Area
Business Wire
a day ago
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Zacks
2 days ago
GILD or VRTX: Which Is the Better Value Stock Right Now?
Insider Monkey
2 days ago
Gilead Sciences, Inc. (GILD): Among Stocks That Analysts Think Will Go Up
Zacks
2 days ago
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
Simply Wall St.
2 days ago
High Growth Tech Stocks in the United States to Watch
Compare GILD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GILD Gilead Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.